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Introduction
Etoposide is an anticancer agent with proven efficacy against several human cancers, including lung cancer. 1 ' 2> The efficacy is cell cycle-dependent, and a significant correlation between duration of drug exposure and cytotoxicity has been demonstrated in vitro., 3) Its administration for three to five consecutive days seems to produce clinical results superior to those obtained by a single dose administration. 24 ' Based on the data indicating the advantages of an extended duration of drug exposure, clinical studies of continuous-infusion etoposide in patients with malignant diseases have been carried out. 5 
"
71 Cisplatin (CDDP) also has antitumor activity against a broad range of cancers, including lung cancer. 8 ' Gastrointestinal toxicity, such as nausea and vomiting, and nephrotoxicity are the doselimiting factors of CDDP, and they seem relatively mild when the drug is administered over a prolonged period. 9 '
l0)
The combination of etoposide and CDDP Received: January 21, 1991 Accepted: July 4, 1991 *For reprints and all correspondence demonstrates therapeutic synergism in vitro, n) and clinical studies of a continuous infusion of etoposide concomitant with CDDP have been carried out. The greater hematologic toxicity may be attributed to the prolonged infusion of etoposide.' 21 The optimal doses of etoposide and CDDP administered in 72-hour infusions are 75 and 30mg/m 2 /day, respectively. 13) For the present study we have investigated the pharmacokinetics of etoposide, 240 mg/m 2 administered continuously for 72 hours concurrently with CDDP, 90 mg/m 2 to 12 lung cancer patients.
Subjects and Methods
The pharmacokinetic evaluation was carried out from August, 1989, to July, 1990, in lung cancer patients. The eligibility criteria included a minimum WBC count of 4,000//il, a minimum platelet count of 100,000//tl, a performance status with a WHO score <3, normal liver function (serum bilirubin <1.3mg/dl, GOT<40IU/1 and GPT<36IU/1) and normal renal function (BUN<21mg/dl and creatinine <1.4mg/dl). Nine men and three women ranging in age from 52 to 76 years, were entered into the study. Table I lists the patients' individu-al characteristics. Ten had non-small-cell lung cancer and two, small-cell lung cancer. Elven patients had received no previous treatment; the remaining one, with small-cell lung cancer, had been treated with cyclophosphamide, doxorubicin and vincristine. The hematological values of this previously-treated patient had completely returned to normal. Informed consent to the treatment and blood sampling was obtained from all patients.
A central venous catheter was inserted 24 hours before treatment, and hydration was initiated at more than 1,500 ml/day. Etoposide (80 mg/mVday) and 30mg/m 2 /day of CDDP were administered separately with pumps. Half the daily doses of etoposide and CDDP were diluted in 500 ml 5% glucose and 500 ml saline, respectively. Both drugs are stable for more than 24 hours under these conditions. Metoclopramide (1 mg/kg) was infused at the beginning of the chemotherapy, and metoclopramide (3 mg/kg/day) and KC1 (20mEq) diluted in 500 ml saline were infused every 24 hours during the chemotherapy. Furosemide (20 mg) was administered at 0, 24, 48 and 72 hours after the initiation of the chemotherapy.
Patients were evaluated for response using traditional criteria: a complete response was defined as the disappearance of all disease; a partial response (PR) as a 50% or greater reduction in the product of the two greatest perpendicular diameters of the tumor for more than four weeks without the appearance of new lesions; no change (NC) as a less than 50% decrease or a less than 25% increase in tumor size with no new lesions; and progressive disease (PD) as a 25% or more increase in the size of one or more lesions, or the appearance of new lesions. Liver function tests, serum creatinine and BUN were monitored at least once a week, and complete blood count and platelet count were monitored at least twice a week.
Pharmacokinetics were evaluated in each patient during the first course of chemotherapy. Blood samples were drawn at 0, 1, 2, 4, 8, 12, 24, 48 and 72 hours during the infusion and 1, 2, 4, 8, 12, 24 and every 24 hours thereafter during the postinfusion period. Serum was separated by centrifugation and was ultrafiltrated in Centrifree MPS-3 (Amicon Corp., Danvers, MA) at l,000g for 20min. Urine samples were collected for each 24-hour period. Serum and urine concentrations of etoposide were determined by high-performance liquid chromatography (Japan Spectroscopic Corp., Tokyo).
14 ' The concentrations of platinum in the ultrafiltrate (free Pt), serum (total Pt) and urine were determined by atomic absorption spectrometry with an atomic absorption spectrophotometer, AA-40 (Varian Techtron, Melbourne, Australia).
'
The elimination half-life (TV£) was calculated from the equation T'/i = ln 2/k where k is the elimination rate constant given by the slope of In concentrations vs time. Non-compartmental pharmacokinetic parameters were calculated. The concentration at steady state (Co) was defined as the mean of the measured serum concentrations of etoposide at 24, 48 and 72 hours after the initiation of the infusion. The area under the concentration vs time curve (AUC) and the area under the moment curve < AUMC = (C x t) w t > for etoposide and free Pt were calculated using the trapezoidal method from zero to the last time measured. In fact, levels of etoposide and free Pt reached the lower limits of sensitivity (0.1/xg/ml and 25ng/ml, respectively). The AUC and AUMC for total Pt were calculated by the trapezoidal method with exponential extrapolation to infinite time. The systemic clearance All data other than half-life are presented as arithmetic means and standard deviations, and the half-life as the harmonic mean and "pseudo standard deviation." 16 ' These pharmacokinetic parameters were determined by the computer program, MULT1.
I7)

Results
The etoposide concentration vs time curve is presented in Fig. 1 . The serum concentration of etoposide increased during the first 24 hours of the infusion and reached a steady level at 24 hours, and no change was observed until 72 hours had passed in each case. The concentrations at steady state were, therefore, calculated as the means of the concentrations at 24, 48 and 72 hours. Serum levels of free Pt were slightly above the lower limit of sensitivity; more than two-thirds of detected levels were lower than 50ng/ml. The intra-assay variability in this range was as large as 20%, and no stable increase or stable steady state was achieved (data not shown).
The pharmacokinetic parameters of etoposide and Pt in the present study are given in Table II . For comparative purposes, the values previously published for patients treated with etoposide alone for various infusion times are summarized in Table JJJ 5,6,18-2D Q ur fa t& were j n accorc j ance w j tn those found in previous reports, although CDDP was administered concurrently in our series. Table IV shows the toxicity. The median nadir of the leukocyte count was 2,400 (range, 1,100-3,100)//tl. No patient suffered from infection. The median nadir of the platelet count was 132,000 (range, 15,000-341,000)//tl, and no platelet transfusions were required. Gastrointestinal toxicities were mild and transient. Transient elevations of creatinine level were observed in two patients.
Ten patients with non-small-cell lung cancer were evaluated for response. Four PR were noted. Four had NC and two, PD. The response of a previously-untreated patient with small-cell lung Table II were tested by linear regression analysis for their possible correlation with the observed hematologic toxicity. The leukocyte nadir was significantly correlated with the AUC (r-0.70, P<0.01), the concentration at steady state (r-0.61, P<0.05) and the total clearance rate (r-0.58, P<0.05). The hemoglobin level and platelet count nadirs were not significantly correlated with the pharmacologic parameters of etoposide. We also tested for correlation between the pharmacologic parameters of CDDP and hematologic toxicity, but no significant correlation was found.
To test whether or not some variables obtained before the completion of chemotherapy could predict the AUC, which was highly predictive of the hematologic toxicity, simple linear regression analysis was performed to identify relations between the AUC of etoposide and the concentration of etoposide at 24 hours or biochemical variables (BUN, Cr, total protein, albumin, total bilirubin, GOT, GPT, alkaline phosphatase, Y-GPT). The concentration at 24 hours (r0.86, P<0.01), total AUC (/ig-hr/ml) bilirubin (rO.65, P<0.05, Fig. 2 ) and total protein (r0.59, P<0.05, Fig. 3 ) were significantly correlated with the AUC of etoposide. Although not significant, a trend was observed towards a relation between serum albumin and the AUC of etoposide. We therefore, tested the predictability of hematological toxicity using these variables, but we were not able to predict the toxicity.
Discussion
Our data on the pharmacokinetic parameters of etoposide administered concurrently with CDDP for 72 hours were in accordance with previously published data for etoposide as a monotherapy, 5 '
6> 18~2 " indicating that the addition of CDDP did not affect the pharmacokinetics of etoposide. A correlation exists between the steady state concentration and the dose per body surface area per day.
3 ' After adjustment for the dose administered, the concentration at steady state in our study was the same as that reported previously (Table III) . The renal clearance of etoposide was lower than that in previous studies using a shorter infusion time, 20 ' 2 " but it was the same as that with a 72-hour infusion, 3 ' suggesting the addition of CDDP not to affect the elimination of etoposide. The reason for the renal clearance being less than that found with a shorter infusion time is unknown.
The concentration vs time curve for free CDDP varied in each patient and no patient achieved a steady state. This variability could be a result of the relatively low concentration of free Pt. Most of the measured concentrations of free Pt were in the range of the large intra-assay variability. Our data on free Pt were, therefore, unreliable and we cannot discuss the pharmacokinetics of CDDP in the present paper.
Most etoposide is bound to protein, and serum albumin and bilirubin concentrations are correlated with the free fraction of etoposide which is available for clearance. 22 ' In the present study, total protein was significantly correlated with the AUC of etoposide, and although not significant, a trend towards a relation between serum albumin and the AUC of etoposide was observed. These findings were in accordance with the inverse relation between serum albumin and the clearance of etoposide.
2 " Recently, Stewart et a/. 23 ' reported the unbound fraction of etoposide to be higher in hyperbilirubinemia patients, although the total clearance of etoposide did not differ between patients with low levels of bilirubin and those with hyperbilirubinemia. In the present study, total bilirubin was correlated with the AUC of total etoposide in patients with normal levels of bilirubin (Fig. 2) .
The exact reason for the correlation being found in a narrow range of bilirubin is unknown. The greatest AUC and the smallest clearance were observed in a patient with the highest level of bilirubin. The highest level of albumin was also observed in this patient (Table I ). The free fraction of etoposide in this patient was very low, according to a model by Stewart et a/. 22 ' This could explain the large AUC in the patient with highest level of bilirubin.
We tested the relation between the biochemical variables which were correlated with the AUC of etoposide and hematologic toxicity, anticipating the variables to predict toxicity, but we could find no significant relation. Our small number of patients and the concurrent administration of CDDP may explain the absence of correlation.
Although the concentration of etoposide at 24 hours was strongly correlated with the AUC, and the AUC was correlated with hematologic toxicity, we failed to verify a significant correlation between the concentration at 24 hours and hematologic toxicity. Bennett et al. S) carried out a pharmacologic study of a 72-hour continuous infusion of etoposide as a single agent, showing the concentrations at 24 hours and at steady state to be significantly correlated with leukocytopenia. Again, the smaller number of our patients and the concurrent administration of CDDP may explain the discrepancy between the two results.
In conclusion, the concomitant administration of CDDP at a dose level of 30mg/m 2 /day may not affect etoposide when administered continuously for 72 hours.
